Report
EUR 13.24 For Business Accounts Only

CHINA TRADITIONAL CHI MEDICINE sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of CHINA TRADITIONAL CHI MEDICINE (HK), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date April 5, 2022, the closing price was HKD 4.36 and its potential was estimated at HKD 5.33.
Underlying
China Traditional Chinese Medicine Holdings Co. Ltd.

China Traditional Chinese Medicine Co is an investment holding company. Through its subsidiaries, Co. is engaged in research and development, production and sale of chinese medicine and pharmaceutical products in the People's Republic of China. Co.'s products include: Yu Ping Feng Granule for strengthening body resistance and improving immunity of the human body; Bi Yan Kang Tablet; Feng Liao Xing Medicinal Wine for rheumatic diseases and bone setting; and Nifedipine Sustained-release Tablet, which is a cerebro-cardiovascular drug.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch